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Abstract There has been very limited study of patients with
chronic disease receiving potentially actionable genomic
based results or the utilization of genetic counselors in the
online result delivery process. We conducted a randomized
controlled trial on 199 patients with chronic disease each re-
ceiving eight personalized and actionable complex disease
reports online. Primary study aims were to assess the impact
of in-person genomic counseling on 1) causal attribution of
disease risk, 2) personal awareness of disease risk, and 3)
perceived risk of developing a particular disease. Of 98 inter-
vention arm participants (mean age = 57.8; 39% female) ran-
domized for in-person genomic counseling, 76 (78%) were
seen. In contrast, control arm participants (n = 101; mean
age = 58.5; 54% female) were initially not offered genomic
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counseling as part of the study protocol but were able to access
in-person genomic counseling, if they requested it, 3-months
post viewing of at least one test report and post-completion of
the study-specific follow-up survey. A total of 64 intervention
arm and 59 control arm participants completed follow-up sur-
vey measures. We found that participants receiving in-person
genomic counseling had enhanced objective understanding of
the genetic variant risk contribution for multiple complex dis-
eases. Genomic counseling was associated with lowered par-
ticipant causal beliefs in genetic influence across all eight
diseases, compared to control participants. Our findings also
illustrate that for the majority of diseases under study, inter-
vention arm participants believed they knew their genetic risk
status better than control arm subjects. Disease risk was mod-
ified for the majority during genomic counseling, due to the
assessment of more comprehensive family history. In conclu-
sion, for patients receiving personalized and actionable geno-
mic results through a web portal, genomic counseling en-
hanced their objective understanding of the genetic variant
risk contribution to multiple common diseases. These results
support the development of additional genomic counseling
interventions to ensure a high level of patient comprehension
and improve patient-centered health outcomes.
Keywords Genetic . Genomic . Counseling . Complex
disease . Causal beliefs . Risk perception
Introduction
The ability to simultaneously analyze multiple genomic risk
variants for common adult-onset disease, and apply this infor-
mation in a meaningful way to patients remains a formidable
challenge. Given the complexity of common health conditions
like diabetes, coronary artery disease and cancer, the applica-
tion of genome-based analyses can provide insight into risk
but is only part of the risk equation (Eichler et al. 2010).
Family health history, medical history and health behavior
attributes (e.g. causal beliefs, lifestyle) must also be factored
into how disease risk is presented to and perceived by the
individual (Dewey et al. 2011; Inglis et al. 2015; Ormond
2013). Influences such as level of education, genetic and ge-
nomic knowledge, numeracy and literacy, and health status
may affect an individual’s ability to understand, process, and
incorporate genomic risk information for common adult-onset
disease (Haga 2014; Haga et al. 2013; Lautenbach et al. 2013;
McBride et al. 2009; O'Neill et al. 2010; Roberts et al. 2014).
Effective genetic counseling should make disease risk in-
formation understandable and personally relevant. To achieve
these goals in the era of genomics, genetic counseling has
incrementally evolved into Bgenomic counseling^, which
takes the traditional diagnosis-focused approach for a single
or few diseases, expands it to a greater number of conditions,
and includes a more prevention oriented approach (Middleton
et al. 2015; Ormond 2013). Presenting genomic risk influ-
ences in the context of non-genetic risk variables through ge-
nomic counseling may help individuals recognize that for
some diseases, the genetic contribution is more significant
(e.g. age related macular degeneration), while for other dis-
eases, lifestyle attributes, such as body mass index (e.g. type 2
diabetes) are paramount. As more genome based tests become
available, it will be important to develop genomic counseling
strategies for providing risk information for diseases with mul-
tiple levels of risk and complexity (Cameron et al. 2012;
Marteau and Weinman 2006; Shelton and Whitcomb 2015).
The study of disease risk perceptions and the impact of geno-
mic counseling on this process may increase understanding of
how genomic risk information could facilitate informed deci-
sions, aid adaptation to personal risk, and influence actions to
improve health outcomes (Cameron et al. 2012; Heshka et al.
2008). Although studies have shown that genetic counseling
can positively affect risk perception for hereditary cancer
(Julian-Reynier et al. 2011; McInerney-Leo et al. 2006) and
for Alzheimer disease (Ashida et al. 2010), research is needed
to assess whether genetic/genomic counseling modifies risk
perception for other diseases (Smerecnik et al. 2009). The
study of the impact of multiplex genomic testing on healthy
individuals has shown perceptions of disease risk were mostly
influenced by prior beliefs about genetic causality of diseases,
and by family history (Shiloh et al. 2015). Little is known
about how participants offered genomic counseling for multi-
ple potentially actionable diseases perceive its potential bene-
fit. Prior studies show that 10% or fewer individuals offered
genetic/genomic counseling for genome based results re-
ceived through online delivery have used this service (Bloss
et al. 2013; Kaufman et al. 2012; Schmidlen et al. 2014).
Patients with chronic disease may have different motiva-
tions for predictive testing and represent more varied socio-
economic status (SES) than Bhealthy^ individuals seeking
predictive genomic risk information. Individuals with a chron-
ic disease may also vary in their understanding and response
to multiple actionable genomic risk reports, and may treat risk
information related to their diagnosis differently than risk in-
formation for other diseases. The Ohio State University-
Coriell Personalized Medicine Collaborative (OSU-CPMC)
was designed as a randomized cohort study to measure the
effects of in-person post-test genomic counseling on patients
with chronic disease (heart failure; hypertension) receiving
multiple personalized and potentially actionable complex dis-
ease reports through a web-based portal (Sweet et al. 2014).
The primary aims of the randomized trial were to explore the
following hypotheses: 1) Is genomic counseling associated
with changes in causal attribution of disease risk and personal
awareness of disease risk among participants with chronic
disease following receipt of multiple genomic results online?
2) Does perceived risk of developing a particular disease
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increase among participants who receive genomic counsel-
ing? We also sought to examine the extent to which genomic
counseling was associated with changes in: disease risk due to
updated/expanded family history collection following assess-
ment by the genetic counselor, genetic/genomic knowledge,
and overall satisfaction.
Methods
Background Participants in the Coriell Personalized
Medicine Collaborative (CPMC) receive multiple potentially
actionable complex disease and pharmacogenomics risk re-
ports through a secure web portal as described by Keller
et al. (2010). All CPMC participants are administered online
surveys that collect demographic, medical and family histo-
ries, lifestyle, and medication information to produce person-
alized risk reports that are based on genetic risk factors, family
history, and non-genetic risk influences (e.g. BMI). All CPMC
participants also have the option to complete an online genetic
education and genetic knowledge survey. The CPMC web
portal also offers text and multimedia format educational
materials and tools that enable study participants to learn
more about basic genetics concepts, complex disease ge-
netics, pharmacogenetics, family history risk, relative risk
and health condition specific summaries detailing disease
etiology, risk factors, treatment and available preventative
or risk reducing actions. Results from primary outcomes
of various trials related to the CPMC have been previously
reported (Gordon et al. 2012; Schmidlen et al. 2016;
Schmidlen et al. 2014; Sweet et al. 2016).
Study Design and Participants To assess the effects of in-
person genomic counseling on patients with chronic disease, a
separate sub-study [The Ohio State University-Coriell
Personalized Medicine Collaborative (OSU-CPMC)] was
conducted on a group of participants enrolled in the larger
Coriell Personalized Medicine Collaborative (CPMC). The
present sample is comprised of 199 out-patients with either
hypertension or congestive heart failure. In addition to
completing CPMC required questionnaires, OSU-CPMC
participants completed baseline (76 question) and follow-up
(90 question) surveys designed to measure perceived risk,
causal attribution and personal awareness of disease risk;
general and relative risk numeracy; genetics/genomics
knowledge; confidence in use of test results, and genomic
counseling satisfaction (if applicable) (Study Schema,
Fig. 1; Survey Questions, Table 1). Additional questions
(e.g. measurement of health behaviors) were also part of the
OSU-CPMC study surveys and will be published separately.
The study was approved by the institutional review boards at
Ohio State and the Coriell Institute for Medical Research.
Informed consent was obtained from all study subjects.
Procedures The OSU-CPMC study procedures have been
described in detail previously (Sweet et al. 2014). In brief,
adult patients diagnosed with either congestive heart failure
or hypertension after 06/2008, and under the care of an OSU
physician, were eligible for study participation. Eligible pa-
tient participants were enrolled in the clinical setting by a
study recruiter who collected a saliva sample and administered
a one-hour educational presentation including access to the
CPMC web portal, the randomization component, back-
ground information on DNA, genes, and single nucleotide
polymorphisms, CPMC test report composition, relative risk
(RR), and the availability of free in-person genomic counsel-
ing. Two hundred forty-eight patients were enrolled after be-
ing identified as study eligible by OSU physicians over a two
year period; 4 additional OSU patient participants were re-
cruited via Research Match, an online NIH research registry
which advertised the study. Saliva samples and consent forms
were sent to Coriell, and unique CPMC web portal accounts
were created. Of the 252 patients enrolled, 42 were removed
from the study because they failed to complete the required
baseline questionnaires (Fig. 2). Genotyping was unsuccessful
on two patients, while an additional nine with heart failure
died after completion of baseline measures but before comple-
tion of follow-up measures. Thus, of the original 252 study
participants, 199 patient participants (99 heart failure, 100
hypertension) completed all required baseline evaluations.
Block randomization was implemented by a computer gen-
erated random number list (Microsoft SQL, Microsoft
Corporation, Redmond, WA, USA) prepared by an investiga-
tor with no involvement in the trial. Participants were stratified
by diagnosis (hypertension or heart failure) and enrolling phy-
sician (n = 20). All 199 individuals were block randomized to
either the intervention arm (98 participants) or control arm
(101 participants), with each arm receiving eight CPMC per-
sonalized disease reports [age related macular degeneration
(AMD), coronary artery disease (CAD), type 1 diabetes
(DM1), type 2 diabetes (DM2), hemochromatosis (HH), mel-
anoma (MEL), prostate cancer (PRO), systemic lupus erythe-
matosus (LUP)] (Sweet et al. 2014). These eight conditions
were chosen given the relative high frequency of the genetic
variant used to assess risk, varied effect size of each genetic
variant on risk (RR 0.08 - >6.0), and because each condition is
potentially actionable via lifestyle modification and/or medi-
cal intervention. The reports present personalized risk infor-
mation as relative risk for each of the 8 conditions, based on
genetic variant, family history and health behavior risk factors
individually, in both graphical and numeric format (Fig. 3).
Participants received an email notice directly from the
CPMC web portal of the availability for online viewing of
their test reports, and that they could choose whether or not
to view each report. If a participant did not view at least one
test report, study personnel contacted them by phone or email
a maximum of five times over a 3-month period. When
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viewing a CPMC test report, participants are initially directed
to a webpage containing written and video-based educational
material describing the specific condition, the role of each risk
factor, and approaches to prevention and treatment.
Participants may choose not to view these educational mate-
rials and to proceed directly to their individual test report.
At the time of test result release, participants also received
separate email notification from the Ohio State genetic
counseling team reminding them of the randomization com-
ponent, their assignment into either the intervention or control
arm, and the availability of genomic counseling. Intervention
arm participants were told they would be contacted for an in-
person genomic counseling session within onemonth of view-
ing at least one of the eight CPMC reports. In contrast, control
arm participants were not initially offered in-person genomic
counseling as part of the study protocol but were reminded
that they were able to access in-person genomic counseling, if
they requested it, 3-months post viewing of at least one test
report and post-completion of the follow-up survey (Fig. 1).
They were also reminded that they could access a CPMC
genomic counselor by phone if necessary for urgent questions.
The study was closed for data analysis on August 22, 2014.
Genomic Counseling Session
Genetic counseling protocols for Mendelian disorders as well
as those available in the context of multiplex genomic studies
INTERVENTION ARM 
In-person genomic counseling at OSU 
scheduled after participant views at least 1 
report 
Legend:   
AMD: Age Related Macular Degeneration 
CAD: Coronary Artery Disease 
CPMC: Coriell Personalized Medicine Collaborative 
DM1: Type 1 Diabetes 
DM2: Type 2 Diabetes 
HH: Hemochromatosis 
LUP: Systemic Lupus Erythematosus 
MEL: Melanoma 
PRO: Prostate cancer 
RCT: Randomized Controlled Trial 
Enrolled participants complete CPMC required baseline surveys: demographics, medical 
history, family history, lifestyle, medications and RCT study-specific survey
Participants randomized to either the intervention arm or the control arm 
Participants receive 8 study reports (AMD, CAD, DM1, DM2, HH, LUP, MEL, PRO) and can 
choose to view or not view each report 
CONTROL ARM 
Access to CPMC genetic counselor by 
phone if desired for questions
CONTROL ARM 
1 MONTH AFTER 1st REPORT VIEWED 
RCT study specific follow up survey issued 
INTERVENTION ARM 
1 MONTH AFTER IN-PERSON GENOMIC COUNSELING SESSION 
RCT study specific follow up survey issued 
CONTROL ARM 
3 MONTHS AFTER REPORT VIEWING
Access to In-Person Genomic Counseling 
at OSU if desired
Fig. 1 Study schematic
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Table 1 Study-specific survey questions
Causal Attributes of Disease
Risk
Baseline and Follow up
How much do you think having a
genetic risk variant determines
whether or not a person will
develop each of the following
conditions?
How much do you think family
history determines whether or not a
person will develop each of the
following conditions?
Howmuch do you think environmental
risk factors (for example, smoking,
poor diet, high Body Mass Index
(BMI)) determine whether or not a
person will develop each of the
following conditions?
Personal Awareness of Risk Baseline
Do you have an increased risk for any
of the following conditions due to
your family history?
Do you have an increased risk for
any of the following conditions
due to your environmental risk
(for example, smoking, poor diet,
high Body Mass Index (BMI))?
Follow up
Do you have an increased risk for any
of the following conditions due to
your family history?
Do you have an increased risk for
any of the following conditions
due to your environmental risk
(for example, smoking, poor
diet, high Body Mass Index
(BMI))?
Do you have an increased risk for any
of the following conditions due to a
CPMC genetic risk variant?
Perceived Risk Follow up
What do you think is your chance of
developing each of the following
diseases in your lifetime?
Numeracy and Genetic/Genomic
Knowledge
Expanded and General numeracy
scale itemsa
If the chance of getting a disease is
10%, how many people out of 100
would be expected to get the
disease?
If the chance of getting a disease is
10%, how many people out of 1000
would be expected to get the
disease?
Imagine that we rolled a fair,
six-sided die 1000 times. Out of
1000 rolls, how many times do
you think the die would come
up even (2, 4, or 6)?
In the ACME PUBLISHING
SWEEPSTAKES, the chance of
winning a car is 1 in 1000. What
percent of tickets to ACME
PUBLISHING SWEEPSTAKES
win a car?
Table 1 (continued)
Relative Risk Numeracy - Investigator
Generated Questions
People without a family history of
coronary artery disease have a 20%
risk to develop coronary artery
disease. People with a family
history have a relative risk of 2.0
(they are 2 times as likely to
develop coronary artery disease as
those without a family history).
What is the risk for someone with a
family history?
If a person has a genetic variant that
gives a relative risk for developing
type 2 diabetes of 1.3, how likely
are they to develop type 2 diabetes
compared to someone with no
copies of that genetic variant?
CPMC: Personal perception of
genetic knowledge
Compared to most people, how would
you rate your knowledge of genetics?
a. Better than most people
b. About average
c. Less than most people
CPMC: Genetic/Genomic
Knowledgeb,c
It is possible to see a gene with the
naked eye
Healthy parents can have a child with
a hereditary disease
The carrier of a disease gene may be
completely healthy
All serious diseases are hereditary
Genes are inside cells
The child of a disease gene carrier is
always also a carrier of the same
disease
A gene is a piece of DNA
A gene is a part of a chromosome
All body parts have all of the same
genes
It has been estimated that a person has
about 20,000 genes
A person’s race and ethnicity can
affect how likely they are disease
Once a genetic marker for a disorder is
found in a person the disorder can
be prevented or cured
Only mothers can pass on genetic
disorders
The onset of certain diseases is
due to genes, environment and
lifestyleb
Each of us has variations in our genes
that make it more likely that we will
get certain diseasesc
A Bcomplex disease^ is a health
condition brought on bymany genes
and lifestyle and environmentd
A single nucleotide polymorphism or
BSNiP^ is a variation present in
some individuals that stretches
across in a large section of DNAd
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were reviewed and content areas catalogued to develop the
design of a structured in-person genomic counseling session
(Bloss et al. 2011; DeMarco et al. 2004; Gollust et al. 2012;
Gordon et al. 2012; Kasparian et al. 2007; Payne et al. 2008;
Sanderson et al. 2009; Schmidlen et al. 2009; Smerecnik et al.
2009; Vassy et al. 2012). The Reciprocal-Engagement Model
of genetic counseling practice, built on the tenets of patient-
centered education, relationship, autonomy, support provision
and facilitative decision-making was used to guide the
counseling process (Veach et al. 2007). In-person genomic
counseling was provided from one of two licensed genetic
counselors. The genomic counseling session, which was
scheduled for one hour but sometimes extended to 1.5 h,
included a review of results for all eight test reports, assess-
ment of medical history, and, in accordance with the recom-
mendations of the National Society of Genetic Counselors
Task Force, construction of at least a 3-generation pedigree
in order to provide a context in which the counselee could
understand the test report risk information and risk assess-
ment (National Society of Genetic Counselors' Definition
Task Force et al. 2006; Smerecnik et al. 2009). Given that
participants have the potential for multiple Bincreased^ risk
variables (genetic variant, family history and health behaviors;
Table SI), Bdecreased^ risk variant(s) for DM1, and differing
ranges of relative risk for each disease (0.08 - >6.0), we de-
veloped a tabular visual display for use in the genomic
counseling intervention which synthesized each of the risk
factors into a one-page document to provide an overall quick
reference summary (Sweet et al. 2014). All individual in-
creased risk variables were highlighted, and risk was also
compared to the general population risk for each disease.
The participant was asked which reports they wanted to re-
view with the counselor, and based on this preference at least
one CPMC report was accessed live via the web portal during
the counseling session to associate with the quick reference
summary. Genomic counseling focused on the risk factors
each participant had for a given disease, to include additional
disease risks identified through comprehensive review of the
medical and family histories, and other health behaviors not
included in the CPMC report. Specific actions to prevent and/
or lower disease risk were also provided. A risk summary
letter providing a focused interpretation of the eight personal-
ized CPMC health condition study reports, the medical and
family histories, recommended screening and preventionmea-
sures, and, if indicated, referral to another medical provider
was then mailed to any participant that received in-person
genomic counseling. The summary letter was also made avail-
able to the OSU health care team through the EPIC® electron-
ic medical record.
Survey Measures
Baseline and follow-up measures included new items devel-
oped from a review of the literature, after review with the
respective study authors, and modified items from existing
CPMC surveys (Jenkins et al. 2007; Keller et al. 2010;
Sweet et al. 2014). Table 1 provides a list of questions for each
of the survey measures discussed below. All survey questions
included in the baseline and follow up were identical with the
exception of, the follow up survey also included one question
on personal awareness of disease risk based on the receipt of
genetic results for each disease; one question on perceived risk
of developing a particular disease; and for intervention arm
participants only, 4 questions on satisfaction with the genomic
counseling process.
Risk Perception
Causal Attributions of Disease Risk
A participant’s causal attribution of risk for each disease was
assessed for each risk factor at baseline and follow-up (e.g.
BHow much do you think having a genetic risk variant deter-
mines whether or not a person will develop each of the fol-
lowing conditions?^) (O'Neill et al. 2010). Five point Likert
scales were used for these items, and ratings were combined
across diseases to generate composite scores of the overall
Table 1 (continued)
OSU-CPMC Study Specific:
Genetic/Genomic Knowledge
If a person has a genetic marker for a
disorder, the person will always get
the disordere
People who have a genetic marker for
a disease are unhealthye
A person's health habits can influence
whether or not their genes cause
diseasef
Individual Questions/
Evaluations
Satisfaction/Confidence in Use of
Resultsg
The genetic counseling session was
about the right length of time I
needed
The genetic counseling session was
valuable to me
The genetic counselor gave me
information I needed
I felt better about my health after
meeting with my genetic counselor
I know what to do with my results
a Source: Lipkus (2001)
b Source: Jallinoja and Aro (1999)
c Source: Christianson (2010)
d Source: Keller (2010)
e Source: Furr (1999)
f Source: O’Neill (2010)
g Source: DeMarco (2004)
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importance a participant placed on genetic variants, family his-
tory, and environment for disease risk. Cronbach’s alphas were
0.88, 0.88, and 0.85, respectively, for these composite items.
Personal Awareness of Risk
We assessed each participant’s personal awareness of risk due
to family history and environmental factors at baseline and at
follow-up for each disease using original matrix format mea-
sures (BDo you have an increased risk for any of the following
conditions due to your family history?^). Personal awareness
of risk based on the addition of a genetic variant for each
disease was then also assessed at follow-up (BDo you have
an increased risk for any of the following conditions due to a
CPMC genetic risk variant?^). Response options for these
questions included: yes, no, not applicable, don’t know, do
not want to answer.
Perceived Risk
To assess each participant’s perceived risk of developing a par-
ticular disease we used a single 5 point Likert scale validated
*Non-compliance was when an individual had not completed the baseline surveys within a 45 day time limit 
Analysis performed 
as per protocol (PP) 
n=171
Total patients enrolled, n=252 
Non-compliant, n=42* 
DNA Sample Failed, n=2 
Completed 
baseline surveys 
n=208 
Deceased 
n=9 
Randomized 
n=199 
Viewed Results 
n=93
Viewed Results 
n=90
Participant contacted 
by OSU to arrange in-
person genomic 
counseling session  
n=86
Participant contacts 
OSU to arrange in-
person genomic 
counseling session  
n=5
Intervention Arm 
n=98 
Analysis performed as intention to treat (ITT)   
n=199 
Had in-person 
genomic 
counseling 
n=5
Control Arm 
n=101
Had in-person 
genomic 
counseling 
n=76 
Fig. 2 Enrollment, study groups,
outcomes
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question at follow-up only [BWhat do you think is your chance
of developing each of the following diseases in your
lifetime?^(McBride et al. 2009)].We compared their responses
to the actual risk for each disease based on the CPMC results.
Genomic Counseling Modification of Disease Risk
To examine the extent to which the genomic counseling inter-
vention (versus control group) was associated with changes in
individual actual disease risk compared to risk conveyed
through the CPMC report, we recorded (1) the number of
CPMC study reports for which family history or lifestyle risk
was modified, (2) the number of new disease risks identified
through additional medical and family history assessment, and
(3) the number of specialty referrals.
Numeracy and Genetic/Genomic Knowledge
As numeracy is associated with an individual’s perceptions of
risk, we adapted four numeracy scales from a previous study
to assess our patient sample (Lipkus et al. 2001). Two original
multiple choice questions were included to evaluate numeracy
regarding relative risk based on family history (CAD) and
genetic variant (DM2), because relative risk is used in the
CPMC test reports (e.g. Bif a person has a genetic variant that
gives a relative risk for developing type 2 diabetes of 1.3, how
likely are they to develop type 2 diabetes compared to some-
one with no copies of that genetic variant?^) (Table 1). All six
numeracy questions were short answer questions scored as
correct or incorrect. Personal perceptions of genetic knowl-
edge were assessed using a single multiple-choice, original
item (BCompared to most people, how would you rate your
Fig. 3 Sample CPMC coronary artery disease report. Solid discs
represent the participant’s relative risk, and vertical cylinders depict the
range of relative risk (RR) values possible for the risk variable. On-line
risk reports are organized using a tabbed approach, with separate tabs for
disease condition information, risk results, limitations, methods or review
educational material. To ensure readability, the CPMC test report design
was informed by multiple rounds of pilot testing conducted by allowing
individuals with no scientific background to review report drafts and
provide feedback
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knowledge of genetics?^. Response options: better than most
people; about average; less than most people).
A genetic/genomic knowledge and genetic education his-
tory survey (Table 1) was used to assess knowledge of
basic genetics, inheritance, influence of gene/environment
interactions on complex diseases, disease susceptibility
and genetic variation. The twenty questions were either
from previously published studies (Christianson et al. 2010;
Furr and Kelly 1999; Jallinoja and Aro 1999; Keller et al.
2010; O'Neill et al. 2010) or formulated for the CPMC parent
study to assess participant baseline genetic/genomic knowl-
edge. Information relating to the genetic knowledge questions
was covered in the participant informed consent process either
as part of the explanation of the personalized medicine study
provided during the consent presentation or within the text of
the informed consent document. Specifically, this included an
explanation of the human genome, genes, chromosomes,
SNPs, complex disease genetics, and drug response.
Information on the following topics was available for all par-
ticipants to view on the CPMC web portal throughout the
course of study: basic genetics concepts, complex disease ge-
netics, pharmacogenetics, family history risk, and relative
risk. Information relating to complex disease genetics, relative
risk, lifestyle and family history risk was also provided during
the in-person genomic counseling session. Knowledge was
assessed using true/false questions scored as correct or incor-
rect. Percent correct was calculated across the sets of these
questions and used as the dependent variable (follow-up)
and covariate (baseline).
Individual Questions/Evaluations
Satisfaction with the content and process of the in-person
genomic counseling session for intervention arm partici-
pants was assessed with 4 items from the 6 item Genetic
Counseling Satisfaction Scale (GCSS)(DeMarco et al.
2004). Items included BI feel better about my health after
meeting with my genetic counselor^; BThe genetic counsel-
ing session was valuable to me^ and BThe genetic counsel-
ing session was about the right length of time I needed^.
We modified one original GCSS item BMy genetic coun-
selor helped me to identify what I needed to know to make
decisions about what would happen to me) to read BThe
genetic counselor gaveme information I needed^. We replaced
two original GCSS items with statements more relevant
for our study (i.e. BI know what to do with my results^;
BAll individuals should meet with a genetic counselor
when receiving this type of disease risk information^).
Modifications of items from the GCSS were not validated
prior to inclusion in this study. The response scale for these
items was: Strongly Disagree, Disagree, Neutral, Agree,
Strongly Agree, and Did Not Want to Answer.
Statistical Analyses
We used two approaches to analysis: BPer-Protocol^ (PP) and
BIntention to treat^ (ITT) (Abraha andMontedori 2010; Gupta
2011). PP analysis is a comparison of the two treatment
groups, and includes only those participants who completed
the treatment (e.g. genomic counseling) as originally allocated.
ITTanalysis means that all study participants whowere enrolled
and randomly allocated to receive genomic counseling were
included in the analysis, and are analyzed in the groups towhich
they were randomized. Per Protocol results are presented as the
primary analyses in the main text, and ITT analyses results are
included in the supplemental results for comparison. More spe-
cifically, the analyses in the main body include only individuals
who completed their Btreatment^ (in-person genomic counsel-
ing or no in-person genomic counseling) according to the group
in which they were randomized. This resulted in the removal
from analyses of five participants from the randomized control
group that had in-person genomic counseling prior to complet-
ing the follow-up survey. One additional individual from the
control group was also removed as they received phone geno-
mic counseling from a CPMC genetic counselor. Therefore, we
had 76/98 (77.6%) of intervention arm participants receiving in-
person genomic counseling; and no control arm participants
(n = 95) receiving in-person genomic counseling in the per
protocol analysis (n = 171). For socio-demographic associations
(n participants = 199), Student’s t-test, Fisher’s exact tests, or
Wilcoxon Rank Sums tests were used as deemed appropriate.
Survey Analyses
In general, survey variables were of one of three types: 1) com-
posite, where multiple questions are combined to get an overall
score (Likert type and percent correct), 2) binary responses (yes/
no, correct/incorrect), and 3) single item Likert-like questions
(ordinal response 1–5), which determined the corresponding
models used for their analyses. 1) For composite measurements
that were summaries across multiple questions, such as percent
correct across genetic knowledge questions or combined Likert
scale questions, linear models were employed with a covariate
for baseline scores (to adjust for baseline differences between
groups) and with additional covariates for gender, age, disease
group, and education level. 2) For dichotomous follow-up mea-
surements (such as correct/incorrect assessment of self-risk),
logistic models were used with covariates for baseline response,
gender, age, disease group, and education level. To determine
whether intervention participants had different knowledge of
their personal risk compared to non-intervention participants,
Fisher’s exact tests were employed. 3) For questions of certainty
of personal disease occurrence (Likert type, but not Likert scale;
that is, analyses of single question responses with a Likert type
response), ordinal logistic models were employed with covari-
ates for baseline response, gender, age, disease group, and
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education level within disease. Cronbach’s alpha (Cronbach and
Warrington 1951) was calculated for Likert type questions
that together addressed a particular general theme as an indi-
cation that the combination of these questions was reliable as
a Likert scale item (Clason and Dormody 1994). Missing
values were assumed to be at random regarding follow-up
responses. False discovery rate (Benjamini 1995) adjustment
was used to correct for multiple testing across main effects
tests (n = 86), and a false discovery rate threshold of 20%
was used to declare significance.
Results
Participant Socio-Demographic and Clinical
Characteristics
Table 2 and Fig. 2 depict enrollment numbers and socio-
demographic information for intervention and control group
participants. There were no significant (p < 0.05) differences
in ethnicity, gender, income or education between intervention
and control group participants, or in separate analyses
(PP/ITT). Sixty-nine percent (n = 137) of participants had an
associate’s degree or higher. There weremoremale participants,
107 (53.8%) than female; and 25 (12.5%) worked in a health
care-related occupation (e.g. nursing). Mean age was 58.1 years
(range from 24 to 94). Of the eight diseases under study, 95
participants had a personal diagnosis of at least one disease
(Table SII). There were 40 subjects with 1 elevated genetic
variant risk variable; 68 subjects with 2 elevated genetic risk
variables; and 87 subjects with 3+ elevated genetic risk
variables (Table SIII). There were no significant differences
between study groups on these variables.
The number of reports viewed by intervention arm partic-
ipants is provided in Table 3. Of 183 (91.4%) study partici-
pants who viewed at least one CPMC test report, and thus
were administered the follow-up survey, 129 (64 intervention
arm; 59 control arm) completed the follow-up survey. Across
Table 2 Socio-demographic and clinical characteristics of intervention versus control group participants
Demographic Category Subject Category Intervention Arm
(n = 76)
Control Arm
(n = 95)
p value Test
Age (mean) 57.8 58.5 0.86 Welch^s t-test
Number of reports viewed (mean) 6.73 0.79 0.61 Wilcoxon Rank Sums
Race (Caucasian) Yes 68 88 0.59 Fisher’s Exact Test
No 8 7
Gender Female 33 49 0.356 Fisher’s Exact Test
Male 43 46
Education <HS 3 0 0.13 Ordinal Logistic
HS Grad/GED 2 10
Vocational/Trade 1 0
Some College 13 23
Associate Degree 12 12
Bachelor Degree 20 24
Graduate Degree 25 26
Received GC Yes 76 0 <0.0001 Fisher’s Exact Test
No 0 95
Follow Up Yes 64 59 0.002 Fisher’s Exact Test
No 12 36
Income <$25 k 5 10 0.24 Wilcoxon Rank Sums
$25-50 k 12 19
$50-75 k 19 14
$$75-100 k 19 17
>$100 k 19 34
Did not want to answer 2 1
Diagnosis HTN 43 44 0.22 Fisher’s Exact Test
HF 33 51
Health Care Occupation Yes 9 13 0.82 Fisher’s Exact Test
No 67 82
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the entire sample, completion was greater than 90% for all
follow up survey questions, with the exception of the last
four questions on the survey regarding genomic counseling
satisfaction. Only 29 (of 76) intervention arm participants
completed these last 4 questions.
Of 98 intervention arm participants, 76 (77.6%) were seen
for in-person genomic counseling. Four individuals did not
show up for their appointment. Of the remaining 18 eligible
intervention arm participants, eight never viewed a CPMC
report; six never scheduled an appointment; and four declined
genomic counseling. The mean number of days from partici-
pant completion of the baseline survey to genomic counseling
was 224; from release of test results to genomic counseling
(90); from viewing test results to genomic counseling (52),
and from genomic counseling to completion of follow-up
survey (168) (Table SIV). The mean number of days from
report viewing to completion of follow-up surveys was com-
parable between groups (intervention, 222; control, 175).
Risk Perception
Causal Attributions of Disease Risk
We examined to what extent intervention arm participants who
had genomic counseling believe that different risk influences
(genetic variant, family history, health behavior) contribute to
a person’s risk for developing each of the eight diseases, and if
receiving genomic counseling was associated with changes,
from baseline in their causal attributes. At baseline, there was
no evidence supporting differences in causal beliefs between the
two groups. In follow-up, genomic counseling was associated
with decreased genetic causal beliefs across all eight diseases,
compared to control participants (estimate = 0.4, raw p = 0.019;
FDR p = 0.142, 95%C.I. 0.06–0.7); Table 4; SV ITT). Here and
throughout the results, estimate refers to the estimate of the
coefficient for the variable of interest in the statistical models.
Additional analyses were then performed for each disease to
determine if only a subset of the diseases might be driving the
association. As seen in Table 4 (SV, ITT), genomic counseling
was positively associated with lowering participants’ causal
beliefs in the degree of genetic variant influence for three
diseases (LUP, raw p = 0.0008, DM1, raw p = 0.010; PRO,
raw p = 0.005; estimates =1.3, 0.92, 1.0, respectively).
Personal Awareness of Risk
Baseline personal awareness of risk, based on two factors,
family history and health behavior, was in general accurate
and highly predictive of follow up awareness of risk for each
disease in each group. Upon examining whether genomic
counseling affected personal awareness of risk (whether sub-
jects correctly reported that they were at increased risk based
on family history and health behavior risk influences), there
was no significant effect of genomic counseling (FDR
p > 0.25) Table SVI). However, we also asked participants
in their follow-up questionnaire whether they knew they had
an increase in disease risk due to a genetic risk variant, and
found that intervention arm participants who had genomic
counseling answered Bdon’t know^ at a lower rate than con-
trol subjects, for six of the eight diseases (FDR p < 0.2;
Table 5; SVII ITT). We then compared the accuracy of par-
ticipants’ personal awareness of disease risk to their actual
genetic variant results; significant associations with genomic
counseling were seen for DM1 and DM2 (FDR p = 0.2 and
0.12, respectively) with more individuals in the genomic
counseling arm accurately describing the risk for DM1 and
DM2 than in the control arm.
Perceived Risk
Lastly, at follow-up, we asked participants to report their per-
ceived risk for developing each of the eight diseases in their
lifetime, and compared those results to their actual risk results.
Althoughwe found nomain effect due to genomic counseling,
participants who had elevated BMI as a risk factor for DM2
(FDR = 0.04), genetic variant risk for DM2 (FDR p = 0.12;
estimate = 2.0; raw p = 0.001), family history risk for MEL
(FDR p = 0.05, estimate = 1.9; raw p = 0.003) or genetic
variant risk for MEL (FDR p = 0.01, estimate = 2.3, raw
p = 0.0002) had an elevated perceived risk for developing
these diseases compared to those without these risk factors
(Table 6; SVIII ITT).
Table 3 Number of risk reports viewed per disease by intervention arm
participants (n = 76)
Disease Pre-Genomic Counseling Post-Genomic Counseling
AMD 71 2
CAD 64 4
DM1 54 5
DM2 55 5
HH 59 6
LUP 54 8
MEL 53 10
PRO 45 10
AMD: Age Related Macular Degeneration
CAD: Coronary Artery Disease
DM1: Type 1 Diabetes
DM2: Type 2 Diabetes
HH: Hemochromatosis
LUP: Systemic Lupus Erythematosus
MEL: Melanoma
PRO: Prostate cancer
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Genomic Counseling Modification of Disease Risk
To examine whether genomic counseling was associated with
changes in individual actual disease risk, we compared the
number of CPMC study reports for which family history risk
was modified based on the collection of a three generation
pedigree, as well as the number of new disease risks identified
through additional family history assessment. We also record-
ed the number of specialty referrals that were made by this
additional risk assessment. Among all study participants (in-
tervention and control arm) who had genomic counseling
(n = 81), family history disease risk was modified for 61
(75.3%; 95% CI 65.9%–84.7%). There were 104 instances
of specific modification of participant disease risk, which
accounted for 6% of all risk variables for which individuals
had a risk determined separately at genomic counseling
(Table 7). Genomic counseling also identified 31 individuals
who were referred for additional genetics evaluation (n = 22)
or increased screening (n = 9) (Table 8).
Numeracy and Genetic/Genomic Knowledge
We used a number of questions to assess participant’s simple
genetic knowledge, complex genomic knowledge, and levels
of numeracy. At baseline, the mean percentage of correct an-
swers on the 14 simple genetic knowledge questions was rel-
atively high (77%), as well as for the six complex disease
questions (75%). Basic genetic knowledge (at baseline) was
associated in the multivariable model with higher levels of edu-
cation (raw p < 0.0001; estimate = 0.04; 95% CI 0.02–0.05).
Furthermore, there was strong evidence that baseline perfor-
mance was highly predictive of follow-up performance on the
numeracy (Tables SIX, SX) and genetic/genomic knowledge
questions (numeracy raw p < 0.0001, estimate = 0.53, 95%
CI 0.40–0.66; simple genetic knowledge raw p < 0.0001,
estimate = 0.54, 95% CI 0.34–0.74; complex genetic knowl-
edge raw p < 0.0001, estimate = 0.45, 95% CI = 0.26–0.65)
suggesting that in a generally highly educated group, geno-
mic counseling did not provide an added knowledge benefit
Table 4 Causal attributes of genetic variant, family history, and environmental disease risk
General Composite Score Across All Eight Diseases Under Study
Estimate CI (lower) CI (upper) Std. Error p value FDR p value
Genetic Variant 0.378 0.06 0.69 0.158 0.019 0.142
Family History 0.089 -0.181 0.358 0.136 0.515 0.744
Environmental 0.096 -0.18 0.37 0.139 0.494 0.744
Additional Analyses: Causal Attributes of Genetic Variant Disease Risk
Disease Risk Factor Estimate Std. Error p Value
AMD Genetic Variant 0.297 0.349 0.395
CAD Genetic Variant 0.369 0.352 0.295
DM1 Genetic Variant 0.923 0.358 0.010
DM2 Genetic Variant 0.108 0.344 0.752
HH Genetic Variant 1.101 0.373 0.003
LUP Genetic Variant 1.274 0.379 0.0008
MEL Genetic Variant 0.574 0.350 0.101
PRO Genetic Variant 1.03 0.365 0.005
Survey Question: How much do you think having a genetic risk variant determines whether or not a person will develop each of the following
conditions?
Null Hypothesis: Genomic counseling does not influence the importance that participants place on a given factor (genetic variant, family history,
environment) on determining disease risk
Estimate: The estimated coefficient in the model for Intervention Arm participants. The range of possible values is –infinity to +infinity
AMD: Age Related Macular Degeneration
CAD: Coronary Artery Disease
DM1: Type 1 Diabetes
DM2: Type 2 Diabetes
FDR: False discovery rate
HH: Hemochromatosis
LUP: Systemic Lupus Erythematosus
MEL: Melanoma
PRO: Prostate cancer
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(FDR p > 0.39) (Tables SXI-SXIII), at least at the difficulty
level of the questions included in the current study.
Individual Questions/Evaluations
Of intervention arm participants who had in-person genomic
counseling, 83.1% (95%CI 70.5–91.2%) expressed confidence
in knowing what to do with test results, as compared to control
arm participants (61.8%; 95% CI 47.7%–74.3%). Likewise
more intervention arm participants who received genomic
counseling (73%; 95% CI 59.5%–83.3%) felt that individuals
should meet with a genetic counselor when receiving these
types of test results, than control arm participants (54.4%;
95% CI 40.6%–67.8%). Only 29 participants who had
in-person genomic counseling completed the 4-question
survey section on satisfaction; of these, 24 (82.7%; 95%
CI 63.5–93.4%) reported feeling better about their health fol-
lowing genomic counseling. Twenty-seven participants (93%;
95% CI 75.8–98.8%) felt the genomic counseling session was
the appropriate length of time. A similar percentage of coun-
selees (93%; 95%CI 75.8–98.8%) felt the genomic counseling
session was valuable, and that the counselor provided needed
information (Table SXIV).
Discussion
In a population of patients affected with chronic disease re-
ceivingmultiple, actionable and personalized complex disease
risk reports through an online portal, we sought to determine if
in-person genomic counseling had an impact on 1) causal
attribution of disease risk, 2) personal awareness of disease
risk, and 3) perceived risk of developing a particular disease.
We found that those receiving genomic counseling had en-
hanced objective understanding of the genetic variant risk
contribution for multiple actionable complex disease reports.
Indeed, participants receiving genomic counseling were sig-
nificantly more likely to understand the relative and limited
predictive contribution of common genetic risk factors for
complex disease compared to control subjects. Participants
receiving genomic counseling also were more confident
and accurate in knowing their genetic risk status than con-
trol subjects, which is consistent with broader literature on
the benefits of genetic counseling (Armstrong et al. 2015).
Furthermore, the more comprehensive assessment of family
history through genomic counseling allowed for disease risk
to be modified in a significant percentage of cases. Our study
participants demonstrated similarly high levels of genetic
knowledge to that reported in the larger CPMC cohort
(Schmidlen et al. 2016) as well as that found by Haga et al.,
who also studied genetic knowledge in the context of com-
mon, complex diseases (Haga et al. 2013). In a highly educat-
ed population of patients provided with genetics/genomics
education during recruitment and with access to online
genetics/genomics educational material prior to genomic
counseling, we did not find significant improvement in
genetics/genomics knowledge or numeracy following geno-
mic counseling. Given that the information assessed by the
genetic knowledge questionnaire was covered at multiple
points during the study recruiting session, discussed in the
informed consent document, and included in the educational
web pages on the CPMC web portal, in addition to the highly
Table 5 Participant awareness of an increase in disease risk due to a
genetic variant
Yes No FET p value FDR p value
n n
AMD
GC intervention 34 23 0.049 0.241
Control 9 35
CAD
GC intervention 36 24 0.02 0.142
Control 27 18
DM1
GC intervention 12 48 0.003 0.050
Control 10 33
DM2
GC intervention 34 26 0.006 0.082
Control 14 30
HH
GC intervention 9 45 0.17 0.453
Control 4 39
LUP
GC intervention 17 40 0.017 0.142
Control 6 36
MEL
GC intervention 19 41 0.002 0.04
Control 6 36
PRO
GC intervention 5 47 0.037 0.197
Control 2 33
Survey Question: Do you have an increased risk for any of the following
conditions due to a CPMC genetic risk variant?
AMD: Age Related Macular Degeneration
CAD: Coronary Artery Disease
DM1: Type 1 Diabetes
DM2: Type 2 Diabetes
FDR: False Discovery Rate
FET: Fisher’s Exact Test
GC: Genomic Counseling
HH: Hemochromatosis
LUP: Systemic Lupus Erythematosus
MEL: Melanoma
PRO: Prostate cancer
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educated population, these findings are not surprising. While
some of the topics covered in the genetic knowledge question-
naire (complex disease genetics, family history risk) were also
reinforced in the genomic counseling session, the focus
of the genomic counseling sessions was on personal risk
assessment and not on a review of the specific genetic/
genomic knowledge items queried.
Previous studies have shown that 1) individuals see distinct
causal roles for genetic variant and health behavior risk influ-
ences for common disease; and 2) these separate causal beliefs
are not incompatible (Kaphingst et al. 2012; McBride et al.
2009; McBride et al. 2015; Sanderson et al. 2009; Shiloh et al.
2015). In fact, for common disease risk, although individuals
may view separate influences on distinct tracks, large seg-
ments of the population also appear to have disparate views
of the relationship between genes and health behavior
attributes on perceived risk (Ashida et al. 2011; Condit and
Shen 2011; Haukkala et al. 2015). O'Neill et al. (2010) found
that healthy individuals, when provided complex disease re-
sults, had a tendency to favor genetic causation over health
behaviors when the number of personal risk factors increased,
which corresponds with our own findings. Our sample of pa-
tients appeared to embrace stronger causal belief in the genetic
influence on common disease risk, possibly due to having
personal experience in dealing with a chronic disease. The
genomic counseling intervention, in addition to providing
more insight into the interrelationship between genetics and
health behaviors as contributors of risk, may also have coun-
tered existing causal genetic deterministic beliefs and emo-
tions predicated by personal disease experience. This may
allow, in turn, greater understanding of the multifactorial
nature of complex disease and an opportunity for additional
Table 6 Perceived risk
Disease Risk Factor Genomic Counseling
p Value
Actual Risk
p Value
Genomic Counseling
FDR p Value
Actual Risk FDR
p Value
AMD Family 0.127 0.270 0.372 0.574
Smoking 0.195 0.968 0.503 1.00
Variant 0.082 0.814 0.307 0.891
CAD Diabetes 0.576 0.506 0.744 0.744
Family 0.234 0.565 0.569 0.744
Smoking 0.296 0.564 0.600 0.744
Variant 0.649 0.071 0.811 0.300
DM1 Family 0.101 0.747 0.334 0.882
Variant 0.043 0.492 0.228 0.744
DM2 BMI 0.467 0.001 0.744 0.043
Family 0.715 0.067 0.868 0.300
Variant 0.813 0.010 0.891 0.119
LUP Family 0.067 0.032 0.300 0.196
Variant 0.109 0.102 0.346 0.333
MEL Family 0.249 0.003 0.572 0.051
Variant 0.077 0.0001 0.307 0.010
Survey Question: What do you think is your chance of developing each of the following diseases in your lifetime?
Null hypothesis: genomic counseling and actual risk do not have an influence on a participant’s belief that they will/will not develop the disease
Hemochromatosis (HH) was not included because there were no participants withHFEmutation (the only reported risk factor) that completed follow up
Prostate cancer (PRO) was not included because the number of participants with a risk factor was too small to estimate using modeling
AMD: Age Related Macular Degeneration
CAD: Coronary Artery Disease
DM1: Type 1 Diabetes
DM2: Type 2 Diabetes
FDR: False Discovery Rate
HH: Hemochromatosis
LUP: Systemic Lupus Erythematosus
MEL: Melanoma
PRO: Prostate cancer
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interventions to improve patient-centered health outcomes
(Austin 2015; Lewis et al. 2015; McBride et al. 2015;
Ormond 2013). As all study participants received pre-test
education during the informed consent session, and had
access to online educational resources, genomic counseling
may also have served to reinforce the test report message, and
increase confidence in use of multi-page, detailed results.
These findings are consistent with previous work showing that
incorporation of evidence-based communication strategies in
the result delivery process result in more accurate interpreta-
tion (Birch 2015; Haga et al. 2014).
As compared to online family history collection and risk
assessment, a three or four generation, more comprehensive
family history was obtained and assessed through genomic
counseling. In this targeted disease population, the assessment
of comprehensive family history resulted in a significant num-
ber of modifications of participant disease risk, to include
identification of individuals for which more targeted testing
or screening was appropriate. For example, the family history
relative risk value chosen by the CPMC for use in the CAD
risk report came from a publication that provided family his-
tory risk assessment for CAD based only on parental history
of CAD (Myers et al. 1990). This points to a limitation of
online familial risk assessments in general, which are based
on what the participant provides, but also what algorithm(s)
the online tool includes, which can often be limited, incom-
plete or incorrect. Via genomic counseling, participants with
possible Mendelian conditions were also identified. The
Table 7 Genomic counseling modification of disease risk due to additional family history assessment
Disease
Variable
Test Report
Risk
Post Genomic
Counseling Risk
Number of
Changes to
Risk
Change Due to
Additional Family
History Obtained
Change Due To
Modification of
Family History
Risk
AMD No Risk Increased 5 5 -
AMD Increased No Risk 2 - 2
Subtotal 7 5 2
CAD No Risk Increased 11 11 -
CAD Increased Moderate* 18 18 -
CAD Increased High** 7 7 -
Subtotal 36 36 -
DM1 No Risk Increased 1 1 -
DM1 Increased No Risk 20 - 20
Subtotal 21 1 20
DM2 No Risk Increased 13 13 -
Subtotal 13 13 -
LUP Increased No Risk 23 - 23
Subtotal 23 - 23
MEL No Risk Increased 2 2 -
MEL Increased No Risk 2 - 2
Subtotal 4 2 2
TOTAL 104 57 47
a Source: Scheuner (2003)
b Source: Scheuner (2010)
AMD: Age Related Macular Degeneration
CAD: Coronary Artery Disease
DM1: Type 1 Diabetes
DM2: Type 2 Diabetes
HH: Hemochromatosis
LUP: Systemic Lupus Erythematosus
MEL: Melanoma
PRO: Prostate cancer
*Moderate: personal or family history of coronary heart disease conferring relative risk of 2.0a
**High: personal or family history suggestive of familial coronary heart disease generally associated with an increased risk (2–5 fold) with risk
increasing based on the number of affected relatives, and early age of diagnosisb
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CPMC family history risks were not designed withMendelian
disease risk detection in mind, but were designed very specif-
ically to the complex diseases included, and usually based on
first-degree relative information. While web tools can be in-
valuable for the purposes of triage (Sweet et al. 2015), they
can also miss the intricacies of a 3–4 generation pedigree
assessment collected and assessed during genomic counsel-
ing. Comprehensive risk assessment by a genetic counselor,
whether by interpreting medical and family histories or by
incorporating genetic variant and health behavior attributes into
the analysis, remains an integral part of the result delivery pro-
cess in genetic/genomic counseling (National Society of
Genetic Counselors' Definition Task Force et al. 2006;
Smerecnik et al. 2009).
Study Limitations
Unlike use of multiplex testing by Bhealthy^ adults, our par-
ticipants were all included due to their diagnosis of a chronic
disease (heart failure or hypertension). We had a number of
individuals who never completed baseline measures, did not
view a single test report, or complete follow-up surveys. The
randomized groups did not fully capture the magnitude of the
genomic counseling vs. no-genomic counseling effects be-
cause some intervention group individuals did not receive
genomic counseling, and some control arm subjects received
genomic counseling. Our recruitment efforts may have bias,
especially for the heart failure cohort, as almost 40% of eligi-
ble participants approached did not have access to a computer
and thus declined participation.We had a higher than expected
patient SES, and the sample was highly educated and predom-
inantly Caucasian. There were self-reported data (e.g. family
history) for the web portal, potentially introducing reporting
bias. We had no control over which CPMC reports partici-
pants selected to view on their own via the web portal, with
the exception of reports reviewed during the genomic counsel-
ing session. During the genomic counseling session, all eight
health condition reports were reviewed with the participant.
Some participants may have gotten more information than
they wanted or had an interest in learning. We had no ability
to track which educational topics were viewed by participants
on the CPMC web portal during the course of study. While
using only two genetic counselors for the in-person genomic
counseling sessions helped to standardize the intervention,
this limits generalizability of study findings. We utilized
portions of published measures, with modification of some
items, and creation of new survey measures. The low
response rate for items evaluating genomic counseling re-
ceived raise caution about the generalizability of these
results. Given the modest sample size, which was not
representative of any particular disease population, and
which may have been underpowered to detect real differences,
these should be considered preliminary results and further
investigation is needed.
Research Recommendations and Practice Implications
Based on the limitations of this study, further research on the
effects of genetic/genomic counseling on patients receiving
multiple, actionable complex disease results in an online for-
mat is necessary. Given the steady increase in the availability
of genomic based results, including those available through
online formats, there remains appreciable need for additional
research on the effectiveness and extension of genetic/
Table 8 Indication for specialty referral
Specialty Area Indication Number of Cases
Cardiovascular Genetics
Cardiomyopathy 9
Familial Hypercholesterolemia 3
Aortic Aneurysm 1
Cancer Genetics
Hereditary breast-ovarian cancer 5
Hereditary colorectal cancer 1
Other hereditary cancer 2
Medical Genetics
Muscular Dystrophy 1
Subtotal 22
High Risk Cardiovascular Screening clinic 6
Inherited Arrhythmia Clinic 2
Nutritional Services 1
Subtotal 9
Total 31
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genomic counseling service delivery beyond traditional refer-
ral reasons (i.e. Mendelian disease risk) and service delivery
approaches (Haga et al. 2014; Lewis et al. 2015; Ormond
2013; Shiloh et al. 2015; Trepanier and Allain 2014). These
include phone (telemedicine) as well as use of e-learning ap-
proaches (both static and interactive) either alone or to sup-
plement counseling (Birch 2015; Haga et al. 2014). Use of
adjunct e-learning approaches and automated family history
risk assessment tools may be an avenue to impact patient
knowledge and improve patient-centered health outcomes
while increasing the efficiency of genomic counseling in-
terventions. The degree of genomic counseling needed will
vary per patient, and per indication. In fact, counseling for
common risk variants may not always require advanced or
specialized counseling from a genetic counselor, but rather
other health care professionals, with supplemental training
in genetics/genomics (e.g. nurses) could help in this manner
(Mills and Haga 2014; O'Daniel 2010; Ormond 2013; Shelton
and Whitcomb 2015).
Conclusion
In conclusion, our findings show that genomic counseling
significantly affected comprehension of the genetic variant
risk contribution when patients were presented with multiple
potentially actionable complex disease reports through an on-
line portal. Our study demonstrates that genetic counselors
can work in many ways to affect patient’s understanding of
risk including: 1) providing appropriate breakdown of the var-
ious components of disease risk (genetic variant(s), family his-
tory, non-genetic influences) when presenting risk for multiple
diseases at the same time, 2) adding additional context to this
risk based on personal and family history, to include compre-
hensive assessment through development of a 3–4 generation
pedigree, and 3) increasing patient understanding by providing
side-by-side comparison of risks factors found in online test
reports, to that provided in a visual one-page summary that
was used in the counseling session. Our findings also suggest
that genomic counseling for common disease risks, especially in
the setting of patients with chronic disease receiving test results
with actionable components, may allow opportunity for addi-
tional patient-centered interventions. Providing insight on the
varied effect of genetic variants on risk, to include the limited
predictive contribution of many of these variants, and as relative
to other risk factors, may allow patients to develop more accu-
rate perceptions of risk and what risks they can modify. Given
that most common diseases are multifactorial in nature, with
potentially actionable components via lifestyle modification
and/or medical intervention, improving patients risk percep-
tions may impact personal utility and efficacy, especially if
supplemented with effective health behavior recommenda-
tions and interventions.
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